We are live on ! Find out more
IONS icon

Ionis Pharmaceuticals
IONS

316 hedge funds and large institutions have $5.72B invested in Ionis Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 89 increasing their positions, 115 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 38

5% more funds holding

Funds holding: 301 → 316 (+15)

2% less capital invested

Capital invested by funds: $5.84B → $5.72B (-$114M)

1.41% less ownership

Funds ownership: 92.58% → 91.17% (-1.4%)

17% less call options, than puts

Call options by funds: $60.9M | Put options by funds: $73.5M

23% less repeat investments, than reductions

Existing positions increased: 89 | Existing positions reduced: 115

29% less funds holding in top 10

Funds holding in top 10: 7 → 5 (-2)

Holders
316
Holders Change
+15
Holders Change %
+4.98%
% of All Funds
7.17%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.11%
New
55
Increased
89
Reduced
115
Closed
38
Calls
$60.9M
Puts
$73.5M
Net Calls
-$12.6M
Net Calls Change
+$1.97M

Top Buyers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
+$24.7M
2
BB
BB Biotech
Switzerland
+$15M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$14.5M
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$13.4M
5
Goldman Sachs
Goldman Sachs
New York
+$13.3M

Top Sellers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
-$64.1M
2
Bank of America
Bank of America
North Carolina
-$31.8M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$28.5M
4
ClearBridge Investments
ClearBridge Investments
New York
-$25M
5
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
-$19.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
WTB
301
Washington Trust Bank
Washington
$3K +$3.18K +58 New
JFGIW
302
Johnson Financial Group Inc (Wisconsin)
Wisconsin
$3K +$3.29K +60 New
CIM
303
Contravisory Investment Management
Massachusetts
$2K – – –
JFA
304
JNBA Financial Advisors
Minnesota
$2K – – –
PGWM
305
Parisi Gray Wealth Management
New Jersey
$2K +$1.97K +36 New
EARNEST Partners
306
EARNEST Partners
Georgia
$2K +$2.69K +49 New
FDCDDQ
307
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.46K – – –
CWM
308
Cranbrook Wealth Management
Michigan
$1K – – –
PCP
309
Proficio Capital Partners
Massachusetts
$1K – – –
QCG
310
Quadrant Capital Group
Ohio
$1K – – –
TCM
311
Tradewinds Capital Management
Washington
$1K +$658 +12 New
Financial Engines Advisors
312
Financial Engines Advisors
California
$1K +$768 +14 New
MOS
313
MGO One Seven
Ohio
$1K +$877 +16 New
CB
314
CNB Bank
Pennsylvania
$1K +$987 +18 New
PCG
315
Private Capital Group
Connecticut
$3 +$2.8K +51 New
AC
316
Ascend Capital
California
– -$6.84M -134,994 Closed
NFA
317
Nationwide Fund Advisors
Ohio
– -$3.88M -76,457 Closed
ACM
318
Asymmetry Capital Management
California
– -$2.84M -55,965 Closed
AC
319
Axon Capital
New York
– -$2.51M -49,500 Closed
CCM
320
Cadence Capital Management
Massachusetts
– -$1.63M -32,215 Closed
Capital Fund Management (CFM)
321
Capital Fund Management (CFM)
France
– -$1.52M -30,038 Closed
Point72 Asset Management
322
Point72 Asset Management
Connecticut
– -$1.27M -25,000 Closed
EA
323
Emerald Advisers
Pennsylvania
– -$1.12M -22,132 Closed
AP
324
AHL Partners
United Kingdom
– -$1.02M -20,092 Closed
SM
325
SG3 Management
Puerto Rico
– -$938K -18,500 Closed
11 12
13
14 15

IONS Hedge Fund Activity: Q4 2017 in Review

316 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q4 2017, worth a combined $5.72B — down 2% from $5.84B a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new IONS positions and 38 closed out — a net gain of 17 holders — while 89 added to existing stakes and 115 trimmed.

The largest buyer was Boxer Capital, opening a new position worth an estimated $24.7M. The largest seller was Deutsche Bank, cutting an estimated $64.1M.

  • 316 institutional investors held Ionis Pharmaceuticals (IONS) as of Q4 2017, up from 301 in Q3 2017.
  • Funds reported $5.72B of Ionis Pharmaceuticals stock for Q4 2017, down 2% quarter-over-quarter.
  • 55 funds opened new Ionis Pharmaceuticals positions in Q4 2017 and 38 closed out, a net change of +17 holders.
  • The largest Ionis Pharmaceuticals buyer in Q4 2017 was Boxer Capital, an estimated $24.7M added.
  • The largest Ionis Pharmaceuticals seller in Q4 2017 was Deutsche Bank, an estimated $64.1M sold.

Based on aggregated 13F filings for Q4 2017.